{
    "title": "114_hr3680",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Co-Prescribing to Reduce Overdoses \nAct of 2016''.\n\nSEC. 2. OPIOID OVERDOSE REVERSAL DRUGS PRESCRIBING GRANT PROGRAM.\n\n    (a) Establishment.--\n            (1) In general.--Not later than 6 months after the date of \n        the enactment of this Act, the Secretary of Health and Human \n        Services may establish, in accordance with this section, a 5-\n        year opioid overdose reversal drugs prescribing grant program \n        (in this Act referred to as the ``grant program'').\n            (2) Maximum grant amount.--A grant made under this section \n        may not be for more than $200,000 per grant year.\n            (3) Eligible entity.--For purposes of this section, the \n        term ``eligible entity'' means a federally qualified health \n        center (as defined in section 1861(aa) of the Social Security \n        Act (42 U.S.C. 1395x(aa)), an opioid treatment program under \n        part 8 of title 42, Code of Federal Regulations, any \n        practitioner dispensing narcotic drugs pursuant to section \n        303(g) of the Controlled Substances Act (21 U.S.C. 823(g)), or \n        any other entity that the Secretary deems appropriate.\n            (4) Prescribing.--For purposes of this section and section \n        3, the term ``prescribing'' means, with respect to an opioid \n        overdose reversal drug, such as naloxone, the practice of \n        prescribing such drug--\n                    (A) in conjunction with an opioid prescription for \n                patients at an elevated risk of overdose;\n                    (B) in conjunction with an opioid agonist approved \n                under section 505 of the Federal Food, Drug, and \n                Cosmetic Act (21 U.S.C. 355) for the treatment of \n                opioid abuse disorder;\n                    (C) to the caregiver or a close relative of \n                patients at an elevated risk of overdose from opioids; \n                or\n                    (D) in other circumstances, as identified by the \n                Secretary, in which a provider identifies a patient is \n                at an elevated risk for an intentional or unintentional \n                drug overdose from heroin or prescription opioid \n                therapies.\n    (b) Application.--To be eligible to receive a grant under this \nsection, an eligible entity shall submit to the Secretary of Health and \nHuman Services, in such form and manner as specified by the Secretary, \nan application that describes--\n            (1) the extent to which the area to which the entity will \n        furnish services through use of the grant is experiencing \n        significant morbidity and mortality caused by opioid abuse;\n            (2) the criteria that will be used to identify eligible \n        patients to participate in such program; and\n            (3) how such program will work to try to identify State, \n        local, or private funding to continue the program after \n        expiration of the grant.\n    (c) Use of Funds.--An eligible entity receiving a grant under this \nsection may use the grant for any of the following activities, but may \nuse not more than 20 percent of the grant funds for activities \ndescribed in paragraphs (4) and (5):\n            (1) To establish a program for prescribing opioid overdose \n        reversal drugs, such as naloxone.\n            (2) To train and provide resources for health care \n        providers and pharmacists on the prescribing of opioid overdose \n        reversal drugs, such as naloxone.\n            (3) To establish mechanisms and processes for tracking \n        patients participating in the program described in paragraph \n        (1) and the health outcomes of such patients.\n            (4) To purchase opioid overdose reversal drugs, such as \n        naloxone, for distribution under the program described in \n        paragraph (1).\n            (5) To offset the co-pays and other cost sharing associated \n        with opioid overdose reversal drugs, such as naloxone, to \n        ensure that cost is not a limiting factor for eligible \n        patients.\n            (6) To conduct community outreach, in conjunction with \n        community-based organizations, designed to raise awareness of \n        prescribing practices, and the availability of opioid overdose \n        reversal drugs, such as naloxone.\n            (7) To establish protocols to connect patients who have \n        experienced a drug overdose with appropriate treatment, \n        including medication assisted treatment and appropriate \n        counseling and behavioral therapies.\n    (d) Evaluations by Recipients.--As a condition of receipt of a \ngrant under this section, an eligible entity shall, for each year for \nwhich the grant is received, submit to the Secretary of Health and \nHuman Services information on appropriate outcome measures specified by \nthe Secretary to assess the outcomes of the program funded by the \ngrant, including--\n            (1) the number of prescribers trained;\n            (2) the number of prescribers who have co-prescribed an \n        opioid overdose reversal drug, such as naloxone, to at least \n        one patient;\n            (3) the total number of prescriptions written for opioid \n        overdose reversal drugs, such as naloxone;\n            (4) the percentage of patients at elevated risk who \n        received a prescription for an opioid overdose reversal drug, \n        such as naloxone;\n            (5) the number of patients reporting use of an opioid \n        overdose reversal drug, such as naloxone; and\n            (6) any other outcome measures that the Secretary deems \n        appropriate.\n    (e) Reports by Secretary.--For each year of the grant program under \nthis section, the Secretary of Health and Human Services shall submit \nto the appropriate committees of the House of Representatives and of \nthe Senate a report aggregating the information received from the grant \nrecipients for such year under subsection (d) and evaluating the \noutcomes achieved by the programs funded by grants made under this \nsection.\n\nSEC. 3. PROVIDING INFORMATION TO PRESCRIBERS IN CERTAIN FEDERAL HEALTH \n              CARE AND MEDICAL FACILITIES ON BEST PRACTICES FOR \n              PRESCRIBING OPIOID OVERDOSE REVERSAL DRUGS.\n\n    (a) In General.--Not later than 180 days after the date of \nenactment of this Act, the Secretary of Health and Human Services (in \nthis section referred to as the ``Secretary'') may, as appropriate, \nprovide information to prescribers within federally qualified health \ncenters (as defined in paragraph (4) of section 1861(aa) of the Social \nSecurity Act (42 U.S.C. 1395x(aa))), and the health care facilities of \nthe Indian Health Service, on best practices for prescribing opioid \noverdose reversal drugs, such as naloxone, for patients receiving \nchronic opioid therapy, patients being treated for opioid use \ndisorders, and other patients that a provider identifies as having an \nelevated risk of overdose from heroin or prescription opioid therapies.\n    (b) Not Establishing a Medical Standard of Care.--The information \non best practices provided under this section shall not be construed as \nconstituting or establishing a medical standard of care for prescribing \nopioid overdose reversal drugs, such as naloxone, for patients \ndescribed in subsection (a).\n    (c) Elevated Risk of Overdose Defined.--In this section, the term \n``elevated risk of overdose'' has the meaning given such term by the \nSecretary, which--\n            (1) may be based on the criteria provided in the Opioid \n        Overdose Toolkit published by the Substance Abuse and Mental \n        Health Services Administration (SAMHSA); and\n            (2) may include patients on a first course opioid \n        treatment, patients using extended-release and long-acting \n        opioid analgesics, and patients with a respiratory disease or \n        other co-morbidities.\n\nSEC. 4. AUTHORIZATION OF APPROPRIATIONS.\n\n    There is authorized to be appropriated to carry out this Act \n$5,000,000 for the period of fiscal years 2017 through 2021.\n\nSEC. 5. CUT-GO COMPLIANCE.\n\n    Subsection (f) of section 319D of the Public Health Service Act (42 \nU.S.C. 247d-4) is amended by inserting before the period at the end the \nfollowing: ``(except such dollar amount shall be reduced by $5,000,000 \nfor fiscal year 2018)''.\n\n            Passed the House of Representatives May 11, 2016.\n\n            Attest:\n\n                                                 KAREN L. HAAS,\n\n                                                                 Clerk."
}